The purpose of the study is to determine which of the two therapies works better at controlling the disease. Participants will be randomly assigned to receive one of the two treatments, followed by regular check‑ups that may include scans such as positron emission tomography-computed tomography to look for any remaining cancer and assessments of overall health and quality of life. The study continues for several months after treatment to monitor how well the disease is controlled and to record any side effects.

The purpose of the study is to evaluate the effectiveness of selpercatinib in patients who have early-stage RET fusion-positive NSCLC and have already undergone surgery or radiation treatment. Participants in the study will be randomly assigned to receive either selpercatinib or a placebo. The study is designed to be double-blinded, meaning neither the participants nor the researchers will know who is receiving the actual medication or the placebo during the trial.

Throughout the study, participants will be monitored to assess the progression of their condition and any potential side effects of the treatment. The trial aims to provide valuable information on whether selpercatinib can improve outcomes for patients with this specific type of lung cancer. The study is expected to continue for several years to gather comprehensive data on the treatment’s effectiveness and safety.

The main aim of the study is to evaluate how safe and well‑tolerated multiple doses of the medicine are in this patient group. Participants will receive a series of injections over several weeks, with regular clinic visits where vital signs, heart rhythm checks, and blood tests are performed to watch for any unwanted effects. Some participants may receive a harmless inactive substance for comparison, but the study staff will not know which person receives which treatment.

During the study period, blood samples are taken to measure the activity of the clotting protein that is low in this condition, and menstrual blood loss is recorded using a simple diary that helps estimate the amount of blood lost each cycle. After the dosing phase, participants continue to be followed for a short time to ensure any delayed effects are captured. All procedures are designed to be as short and comfortable as possible.

Participants who have finished first‑line chemotherapy and are either in complete remission (no detectable cancer) or have stable disease are randomly assigned to one of the two groups. They take the study medication daily for a defined period while regular check‑ups, scans, and questionnaires about quality of life are performed. The study follows each participant for several years to record any return of cancer, new health problems, or death, and the information is used to compare the two treatment approaches.

During the study, participants will be monitored over a period of time to see how the medication affects the occurrence of major health events. These events include myocardial infarction, commonly known as a heart attack, stroke, or being hospitalized due to heart failure. The study also looks at coronary revascularization, which is a procedure used to improve blood flow to the heart, and any deaths caused by any reason.

Participants will receive a series of injections of either the study drug or the placebo over several months, with regular clinic visits for safety checks and simple breathing tests. One key breathing test measures the amount of air expelled in the first second of a forced breath, known as Forced Expiratory Volume in 1 second, to see how lung function changes. Throughout the study, people will complete questionnaires that assess health status and symptoms, such as the SGRQ-C (a quality‑of‑life survey), the CAAT (a symptom score), and the E-RS:COPD diary (records daily breathing problems). Researchers will also monitor for any side effects, using terms like TEAEs (any undesirable effects), AESIs (specific safety concerns), and SAEs (serious problems). Blood samples will be taken to check the drug level and to look for antidrug antibodies, which are the body’s immune response to the medication.

Participants are randomly assigned to receive either the lower or the standard dose of the albumin infusion at the time of the fluid‑removal procedure and are then followed for up to one year. During this period, they will have regular clinic visits where blood tests and simple questionnaires are used to check for any new health issues, such as infections of the abdominal fluid (spontaneous bacterial peritonitis), kidney problems caused by liver disease (hepatorenal syndrome – acute kidney injury), bleeding from enlarged veins in the esophagus (variceal bleeding), or changes in brain function due to liver failure (hepatic encephalopathy). The study also records overall well‑being and any hospital visits, but no technical details of the measurements are provided.

During the study, volunteers will attend regular clinic visits over about 12 weeks. At each visit, doctors will check how the disease is doing using a scoring system called the Modified Mayo Score, which looks at symptoms, a visual exam of the colon (called an endoscopic exam), and lab results. A “clinical remission” means the person’s symptoms have become minimal or disappeared, while a “clinical response” means the symptoms have improved but may not be completely gone. An “endoscopic improvement” indicates that the lining of the colon looks better when viewed with a camera, and “histologic” improvement means that tissue samples show less inflammation under a microscope. Safety will be monitored by recording any side effects and noting if anyone stops the treatment because of them.

The main goal of the trial is to evaluate the long‑term safety and tolerability of the study drug in people with the condition. After an initial screening, participants receive the medication at regular intervals for an extended period, during which doctors monitor vital signs, blood tests, heart recordings, and physical examinations. Simple walking and climbing tests are performed at the start and at later visits to see how the treatment may affect mobility.

Throughout the study, blood samples are taken to measure how much of the medicine remains in the body and to check for any immune response. All observations are recorded to help determine whether the therapy is safe for continued use over time.

After the surgery, each person receives the assigned injection—either under the skin (subcutaneous) or into a muscle (intramuscular)—on a schedule set by the study team. Follow‑up visits are planned regularly to check health, monitor any side effects, and assess overall well‑being.

During the study, doctors will watch for any adverse events (unwanted health problems) and ask participants to complete questionnaires about their quality of life and daily functioning. This information helps determine if the treatment is safe and if it improves outcomes compared with the control injection.

Participants in the study will take lasmiditan as needed for their migraine attacks over a 12-month period. The study will monitor how well the medication is tolerated by the participants and will track any side effects that may occur. The study will also look at how many participants stop using the medication due to any adverse effects.

Throughout the study, participants will be closely observed to ensure their safety and to gather information on how lasmiditan works in treating migraines in children. This research aims to provide valuable insights into the long-term use of lasmiditan for managing migraines in pediatric patients.

The purpose of the trial is to determine whether MK-1045 can achieve a higher rate of complete remission (no detectable cancer) and improve overall survival (how long participants live) compared with blinatumomab. Participants will receive a series of treatment cycles lasting several weeks, during which doctors will monitor for adverse events (side effects) and check for minimal residual disease negativity (absence of tiny amounts of cancer cells). Some participants may later undergo allogeneic hematopoietic stem cell transplantation, a procedure that replaces diseased blood‑forming cells with healthy ones from a donor, if deemed appropriate by their physicians.

Participants will receive the assigned tablet daily and the infusion every few weeks, with regular clinic visits for safety checks, blood tests and imaging scans such as CT scans to look for changes in tumor size. The study will continue until the disease gets worse, a participant stops treatment, or the trial ends. Researchers will record how long the cancer stays stable (progression‑free survival), overall survival, side effects, and quality‑of‑life questionnaires.

The purpose of the trial is to identify a safe and effective dose of the new medication, to see how well it works against these cancers, and to understand how it interacts with other treatments. Early parts of the study increase the dose to find the highest amount patients can tolerate, followed by later parts that treat specific cancer types either alone or combined with the listed drugs. A small group of participants will also receive medicines that are processed by the enzymes CYP3A4 and CYP2C8 to check for possible drug‑interaction effects.

Participants will take the study tablet each day and receive the other medicines by intravenous infusion, meaning the drugs are given through a vein. Regular clinic visits will include physical checks, blood tests, and imaging scans that are evaluated using RECIST criteria, a system that measures how tumor size changes over time. The trial will continue for several months, with close monitoring for side effects, dose adjustments if needed, and assessments of tumor response.

Participants in the study will receive an injection of a solution called Radelumin, which contains a substance that helps highlight areas of cancer during the PET/CT scan. The study will compare the results of the PET/CT scans with the findings from a biopsy, which is a procedure where a small sample of tissue is taken from the body to be examined under a microscope. This comparison will help determine the accuracy of the PET/CT scans in identifying cancer spread.

The study will be conducted over a period of time, during which participants will undergo the PET/CT scan and have their results analyzed by three independent experts who are not aware of the patients’ clinical information. This approach ensures an unbiased assessment of the imaging technique’s effectiveness. The study aims to provide valuable information that could improve the diagnosis and treatment planning for patients with high-risk prostate cancer.

Participants will receive a single injection of the imaging agent, followed by a series of imaging sessions that combine PET and CT scans to look at the transplanted kidney, nearby lymph nodes, spleen, liver and bone marrow. A small blood sample will also be taken to measure immune cells using a laboratory technique called flow cytometry. The study lasts for a short period of time after the injection, during which the imaging and blood tests are performed to assess the distribution of the agent and the activity of immune cells.

The purpose of this research is to evaluate how safe DYNE-101 is and how well patients tolerate it when given multiple doses. The study will also examine how the medication affects muscle tissue in people with Myotonic Dystrophy Type 1. The medication being tested is a specially designed antibody that targets specific proteins in the body.

During the study, participants will receive multiple doses of either DYNE-101 or placebo through an intravenous line. The study will involve various assessments of muscle strength and function, including tests of hand grip strength and walking ability. Participants will also undergo muscle tissue sampling to evaluate how the medication affects their muscle cells.

The purpose of the study is to see whether oral semaglutide can help slow worsening of memory, thinking, and daily function in people with early Alzheimer’s disease, and to check its safety. The study is randomised, which means the treatment is assigned by chance, and double-blind, which means neither the participants nor the study team knows who receives semaglutide or placebo during the study. Treatment is taken by mouth over a long period, and the study follows changes over time.

Participants take the study tablets regularly and are seen at planned visits during the trial. These visits are used to monitor health, review how the person is doing, and record any changes in memory, daily activities, or side effects. The study compares how people do over time in the semaglutide and placebo groups.

People in the study are assigned by chance to receive either inclisiran or placebo, and neither the participants nor the study team knows which one is given. The study follows participants over time while they receive the injections and are checked regularly for major heart-related problems such as myocardial infarction (heart attack), ischemic stroke (stroke caused by a blocked blood vessel), death from heart disease, or urgent procedures to open blocked heart arteries. The main purpose of the study is to find out whether inclisiran lowers the risk of these serious events better than placebo.

The purpose of the trial is to evaluate the safety and efficacy of the new combination therapy. Over a period of about four weeks, subjects will take the study medication once daily, while other participants receive a matching placebo. Safety will be monitored through reports of any side effects, regular blood tests, standard 12‑lead ECG recordings to check heart rhythm, and measurements of Sweat chloride levels, which reflect how the disease is affecting the body.

Effectiveness will be assessed by measuring lung function using the percent predicted forced expiratory volume in one second (ppFEV1) and by having participants complete a disease‑specific questionnaire that evaluates breathing symptoms (CFQ R). The study involves several clinic visits for these tests and for overall health checks.

Participants will take the assigned drug pair for several months while continuing usual care. During the study they will have regular visits for blood and urine samples, simple pain questionnaires, and brief physical checks. The laboratory work will look at levels of inflammation‑related proteins and cytokines to understand any changes, and safety will be monitored by recording any unwanted effects or abnormal test results. The overall goal is to determine whether the drug combinations can reduce pain, lower inflammation, and affect the aging markers measured at the start and end of the trial.

Participants are assigned to one of the study treatments and receive injections over time during regular study visits. The study team follows how the cancer responds and watches for side effects and other health changes. It also looks at how long the treatment effects last and how the treatments affect daily well-being and symptoms.

People in the study are assigned to one of the two medicines. The treatment is given over time as intravenous infusions, which means medicine is put directly into a vein. The study is double-blind, which means the people taking part and the study doctors do not know which treatment is being given. During the study, doctors follow how the cancer changes, watch for side effects, and check how well each medicine is tolerated.

After the earlier treatment has finished, participants are assigned to receive either pumitamig or durvalumab. The study is randomized, which means the treatment is chosen by chance, and open-label, which means the treatment is known. The study team then follows the cancer over time and watches for changes, such as whether it stays stable, shrinks, or grows, and also checks how safe each medicine is and how well it is tolerated.

The purpose of the study is to see which medication provides better control of the disease after one year. Participants will receive their assigned medication regularly for up to 52 weeks, with scheduled doctor visits to check how they feel and to perform simple tests that look for signs of healing. The main goal is to determine whether patients achieve “deep remission,” meaning they have no symptoms and their intestinal lining looks normal.

The purpose of this study is to test the safety of ALE.P03 and find the right dose to use, and then to see how well it works against these types of cancer. The study is divided into two main parts called Phase 1 and Phase 2. In Phase 1, different doses of the medication will be tested in small groups of patients to see which dose is safest and best tolerated. During this part, doctors will carefully watch for any side effects and check how the body handles the medication. In Phase 2, the chosen dose will be given to a larger group of patients to see how well the medication works at shrinking or controlling the cancer.

Patients joining this study must have already received standard treatments for their cancer, which may have included chemotherapy, certain antibodies that help the immune system fight cancer, and other medications depending on the type of cancer. The study requires a sample of tumor tissue to be tested in a laboratory to confirm that the CLDN1 protein is present at high enough levels. During the study, patients will have regular check-ups that include blood tests, physical examinations, heart monitoring using ECG, and scans to measure the size of the tumors. The doctors will track any side effects, measure how much medication is in the blood over time, and check whether the body develops an immune response to the medication. The study will continue until 2029.

The purpose of this research is to determine if SNG001 is safe and effective for treating patients on ventilators who have viral respiratory infections. The study is divided into two parts – the first part will look at the safety of the treatment, while the second part will compare SNG001 to placebo to see how well it works. Patients will receive either SNG001 or placebo through a nebulizer while they are on a ventilator.

During the study, doctors will monitor patients’ recovery, including how long they need to stay in the intensive care unit, how long they need ventilator support, and whether the treatment helps them recover from their viral infection. The treatment period will last up to 14 days, and patients will be monitored for up to 28 days to assess their recovery.

The purpose of the study is to compare how well the two medicines lower the level of LDL-C after about 12 weeks. After a screening visit, participants are randomly assigned to one of the two groups. They take the assigned tablets every day for roughly three months, with clinic visits at the start, midway, and at the end to collect blood samples and check safety.

Safety is monitored through regular physical checks, blood pressure measurements, and laboratory tests that look for any side effects. The overall aim is to see which medicine provides a greater reduction in the harmful cholesterol while being well tolerated.

The purpose of the study is to evaluate PFS at 12 months compared with historical results. After the first infusion, patients return for regular treatment sessions over several months while doctors monitor the cancer for any signs of growth or spread, record any side effects that are related to the immune system, and assess overall well‑being. PFS means the length of time a person lives without the disease getting worse. Immune‑related side effects are reactions that happen because the treatment activates the body’s own defenses, and quality of life refers to how a person feels and functions during the study.

People in the study are assigned by chance to receive either RO7795068 or placebo, and neither the participants nor the study team know which one is being given. The study lasts for about 72 weeks. During this time, the treatment is given regularly, and the study team checks body weight, general health, and possible side effects. The study also looks at changes in waist size, blood sugar, blood fats, blood pressure, eating habits, and quality of life.

Possible side effects, changes in blood tests, heart tracing results, and other safety checks are monitored throughout the study. The trial is designed to find out whether RO7795068 can help with weight management in adults with obesity or overweight who do not have type 2 diabetes.

The purpose of this study is to find out whether the study medications are better than placebo at reducing the occurrence of major liver-related complications. During the study, researchers will monitor participants for various liver problems including progression to cirrhosis (severe liver scarring), development of complications like varices (enlarged veins in the digestive tract), ascites (fluid buildup in the abdomen), hepatic encephalopathy (brain function problems caused by liver disease), and other serious liver conditions. The study will also track whether participants need liver transplantation or experience other serious outcomes.

Participants in this study will receive their assigned treatment over an extended period while being regularly monitored by the study team. The study requires participants to have evidence of liver fat confirmed by MRI (a type of imaging scan) and liver scarring confirmed through non-invasive tests, though a liver biopsy is not required to join the study. Throughout the study, participants will have regular check-ups and assessments to evaluate how well the treatment is working and to monitor their liver health and overall wellbeing.